UCB stock gains 1.49 percent after BIMZELX data

Published on 10/04/2026 at 20:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock gained 1.49 percent on October 2 after BIMZELX data showed 47.4 percent complete lesion resolution at three years. HY 2026 sales reached EUR 4.27 billion.

Aquarellmalerei der Brüsseler Skyline mit historischen Türmen und modernen Bürotürmen bei Sonnenuntergang — UCB S.A., ISIN BE0003739530, dargestellt durch stimmungsvolles Aquarell der Brüsseler Skyline bei Sonnenuntergang, Illustration mit AI erstellt.

UCB stock (ISIN BE0003739530) was last at EUR 204.30 on Euronext Brussels on October 2, 2026, up 1.49 percent from the previous close. The move followed UCB's September 30 data release on BIMZELX in hidradenitis suppurativa, where earlier treatment produced complete inflammatory-lesion resolution in 47.4 percent of patients at three years versus 33.3 percent after longer disease duration, according to UCB.

BIMZELX data sharpen the growth case

The EADV 2026 findings add a longer-term clinical dimension to UCB's commercial strategy. Among biologic-naive patients, complete draining-tunnel resolution reached 67.3 percent at three years, compared with 47.7 percent among biologic-experienced patients, while 30.7 percent of treated patients had no active or non-active tunnels after one year versus 14.5 percent at baseline, according to UCB.

The commercial backdrop is already substantial. UCB's investor materials show BIMZELX sales of EUR 1.52 billion in HY 2026, alongside EUR 239 million for FINTEPLA, EUR 192 million for RYSTIGGO and EUR 139 million for ZILBRYSQ, giving investors several quantified growth drivers beyond a single clinical readout.

Revenue and pipeline provide scale

UCB reported HY 2026 revenue of EUR 4.27 billion, up 22 percent, while EBITDA rose 68 percent, according to the September 23 investor update summarized by Quartr. The same update said UCB lifted BIMZELX peak-sales guidance to at least EUR 7 billion, although pricing changes and competition in hidradenitis suppurativa remain commercial variables.

UCB also presented generalized myasthenia gravis data from September 29 through October 2, including interim Phase 1b results for investigational cizutamig, according to UCB. That pipeline breadth matters because mature products such as CIMZIA and BRIVIACT face exclusivity pressure identified in the company's investor discussion.

Analyst target remains above the stock

The analyst consensus published by Trivano was Buy-equivalent, based on 21 analysts, with an average target of EUR 290.00. That target stands 41.99 percent above the EUR 204.30 price, while the latest listed calls included Barclays at EUR 260.00 and Berenberg at EUR 305.00 on October 2, 2026, according to Trivano. The spread between the market price and consensus target makes execution on BIMZELX access, pricing and pipeline launches the central valuation question.

UCB stock remains below its yearly high

UCB stock was last at EUR 204.30 on Euronext Brussels on October 2, 2026, with a session range of EUR 200.20 to EUR 205.20. The 52-week range was EUR 200.20 to EUR 289.50, while market capitalization stood at EUR 38.9 billion and volume reached 176,155 shares.